Retrospective Study of Romiplostim for Platelet Engraftment After Allo-HSCT

NCT07747246 | Completed

• 1 other identifier: DHZ1962-R
• Study Type: observational
• Target: 103
• Locations: 1 country
• Sites: 1

Brief Summary

This is a retrospective observational study evaluating the efficacy and safety of romiplostim for promoting platelet engraftment in patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) at Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology between January 2025 to May 2026. Medical records were reviewed to collect data on platelet recovery time, transfusion requirements, and adverse events. The primary endpoint was time to platelet engraftment. Secondary endpoints included platelet recovery kinetics, transfusion requirements, transplant-related complications, and safety outcomes.No interventions were assigned as part of this study.

Conditions

Thrombocytopenia

Outcome Measures

Primary Outcomes (1)

• Time to Platelet Recovery to ≥50×10⁹/L

  Time from allogeneic hematopoietic stem cell transplantation (Day 0) to the first date of achieving platelet count ≥50×10⁹/L without transfusion support in the preceding 7 days.

  up to Day 100

Secondary Outcomes (2)

• Time to Platelet Engraftment

  up to Day 100

• Time to Neutrophil Engraftment

  up to Day 60

Study Arms (2)

Romiplostim Group

Patients who received romiplostim after allogeneic hematopoietic stem cell transplantation for platelet engraftment.

Control Group

Patients who did not receive romiplostim after allogeneic hematopoietic stem cell transplantation.

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients who underwent allo-HSCT at Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology (Wuhan, China) from January 2025 to May 2026.

You may qualify if:

• Patients diagnosed with AA, AL, MDS, PMF, or other hematologic diseases according to internationally accepted diagnostic criteria
• Patients who underwent allo-HSCT during the study period
• Patients with complete clinical characteristics, transplantation records, and follow-up data

You may not qualify if:

• Primary graft failure;
• Death before hematopoietic engraftment
• Missing key clinical data;(4) Use of thrombopoietin receptor agonists other than romiplostim

Sponsors & Collaborators

• Tongji Hospital: lead

Study Sites (1)

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430030, China

Location

MeSH Terms

Conditions

Thrombocytopenia

Condition Hierarchy (Ancestors)

Blood Platelet Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Cytopenia

Study Officials

• wen

  Tongji Hospital Affiliated to Tongji Medical College of Huaz- hong University of Science and Technology

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor of Hematology

Study Record Dates

• First Submitted: July 27, 2026
• First Posted: August 5, 2026
• Study Start: January 1, 2025
• Primary Completion: May 1, 2026
• Study Completion: July 15, 2026
• Last Updated: August 5, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)